Get 50% OFF This Summer!

Advertisement
logo

Aarti Drugs

AARTIDRUGS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Aarti Drugs Share price and Fundamental Analysis

View All Details
View All Details
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations.
Company Incorporation1984
ChairmanPrakash M Patil
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
3,844.26
PE Ratio
22.86
Industry P/E
31.29
PEG Ratio
-11.8
ROE
12.28%
ROCE
12.48%
ROA
6.53%
Total Debt (Cr)
515.58
Debt to Equity
0.45
Dividend Yield
0.24%
EPS
18.29
Book Value & P/B
136.18 x 3.07
Face Value
10
Outstanding Shares(Cr)
9.19
Current Ratio
2.64
EV to Sales
1.86

Included In

+More

Stock Returns

1 Week+19.41%
1 Month+29.58%
6 Months-12.67%
1 Year-9.52%
3 Years-1.59%
5 Years+93.55%

CAGR

1 Year CAGR

Revenue Growth

-6.9%

Net Profit Growth

+3.15%

Operating Profit Growth

+4.12%

Dividend Growth

0%

Stock Returns CAGR

-11.26%
no_data

No Stocks

Smart Score

2.5
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 55.48%

FIIs : 2.25%

DIIs : 9.70%

Public : 32.57%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
Promoter Shareholding Increased by 0.09% to 55.48% in March 2025 Qtr
DII Shareholding Increased by 0.94% to 9.7% in March 2025 Qtr
FII Shareholding Decreased by 0.03% to 2.25% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Aarti Drugs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Aarti Drugs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations.

The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.

The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide.

Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company.

During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg.

During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur.

During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.

During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg.

During the year 2009-10, the company carried out process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg.

A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012.

During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh.

During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs.

In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.

Aarti Drugs Share Price

Aarti Drugs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Aarti Drugs Market Cap

Market capitalization of Aarti Drugs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Aarti Drugs is valued compared to its competitors.

Aarti Drugs PE Ratio

Aarti Drugs PE ratio helps investors understand what is the market value of each stock compared to Aarti Drugs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Aarti Drugs PEG Ratio

The PEG ratio of Aarti Drugs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Aarti Drugs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Aarti Drugs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Aarti Drugs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Aarti Drugs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Aarti Drugs Total Debt

Total debt of Aarti Drugs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Aarti Drugs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Aarti Drugs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Aarti Drugs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Aarti Drugs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Aarti Drugs Technical Analysis

Technical analysis of Aarti Drugs helps investors get an insight into when they can enter or exit the stock. Key components of Aarti Drugs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Aarti Drugs shares often struggle to rise above due to selling pressure.

Aarti Drugs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Aarti Drugs ’s financial health and profitability.

Aarti Drugs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Aarti Drugs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Aarti Drugs Financials

The financials of Aarti Drugs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Aarti Drugs Profit and Loss Statements

The profit and loss statement of Aarti Drugs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Aarti Drugs .

Aarti Drugs Balance Sheet

The balance sheet presents a snapshot of Aarti Drugs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Aarti Drugs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App